Mutations in the MECP2 gene cause Rett syndrome (RTT). Bdnf is a MeCP2 target gene; however, its role in RTT pathogenesis is unknown. We examined Bdnf conditional mutant mice for RTT-relevant pathologies and observed that loss of BDNF caused smaller brain size, smaller CA2 neurons, smaller glomerulus size, and a characteristic hindlimb-clasping phenotype. BDNF protein level was reduced in Mecp2 mutant mice, and deletion of Bdnf in Mecp2 mutants caused an earlier onset of RTT-like symptoms. To assess whether this interaction was functional and potentially therapeutically relevant, we increased BDNF expression in the Mecp2 mutant brain with a conditional Bdnf transgene. BDNF overexpression extended the lifespan, rescued a locomotor defect, and reversed an electrophysiological deficit observed in Mecp2 mutants. Our results provide in vivo evidence for a functional interaction between Mecp2 and Bdnf and demonstrate the physiological significance of altered BDNF expression/signaling in RTT disease progression.
Introduction
Rett syndrome (RTT), first described by Andreas Rett in 1966, is a neurological disorder that predominantly affects girls (Hagberg, 1985; Hagberg and Hagberg, 1997) . The disease occurs in children of all races and has an estimated prevalence of 1 in 10,000-15,000 girls. The first sign of illness is the deceleration of head growth that begins between 2 and 4 months of age. Patients show rapid developmental regression between the ages of 1 to 3 years. Predominant features include social withdrawal, loss of previously acquired skills, including purposeful hand use and expressive language, and gait ataxia. At this stage, many patients also develop stereotypic movement of the hands and autonomic dysfunctions such as respiratory distress. With extensive care, patients may survive into adulthood, yet they are severely mentally retarded.
Mutations in the X-linked MECP2 gene (methyl-CpG binding protein 2) account for close to 80% of RTT cases Van den Veyver and Zoghbi, 2000; Wan et al., 1999; Xiang et al., 2000) . To study the RTT disease mechanism, we and others established mouse models by engineering Mecp2 gene deletions Guy et al., 2001; Shahbazian et al., 2002) . Mutant males develop normally until 5 weeks of age, when the first manifestations resembling RTT-like symptoms are observed, including reduced brain weight, decreased CA2 neuron size, hindlimb clasping, and impaired locomotor function Guy et al., 2001) .
MeCP2 was initially identified as a protein that specifically binds to methylated DNA in vitro and represses transcription from methylated promoters both in vitro and in vivo (Lewis et al., 1992; Nan et al., 1997) . MeCP2 associates with a core repressor complex containing the transcriptional repressor mSin3A and histone deacetylases (Jones et al., 1998) , suggesting that MeCP2 may function as a molecular linker between DNA methylation, chromatin remodeling, and subsequent gene silencing (Bird and Wolffe, 1999 ). Yet, relatively few expression changes have been identified in Mecp2 mutants that might explain the underlying molecular basis for RTT disease progression (Chen et al., 2003; Horike et al., 2005; Nuber et al., 2005; Tudor et al., 2002) . And the functional consequences of these expression changes have not been studied in vivo. In addition, MeCP2 was recently implicated in regulating RNA splicing (Young et al., 2005) .
One MeCP2 target is a neuronal activity-dependent gene, Bdnf, which encodes a neurotrophic factor essential for neuronal survival (Bonni et al., 1999) , differentiation (Ghosh et al., 1994) , and synaptic plasticity (Poo, 2001) . In cultured neonatal cortical neurons, basal Bdnf transcription is repressed by MeCP2 in the absence of neuronal activity, but activity-dependent upregulation of Bdnf is unaffected by Mecp2 deletion (Chen et al., 2003) . Based on these results, one would predict that, when all the neurons are silent, the Mecp2 mutant brain should express more BDNF than the wild-type brain does at the basal level; yet when all the neurons are active, the Mecp2 mutant brain should express the same amount of BDNF as the wild-type brain does at the highly induced level. However, these predictions are made under the assumption that the level of neuronal activity is the same in both the wild-type and Mecp2 mutant brain. We recently reported reduced cortical activity in the Mecp2 mutant brain (Dani et al., 2005) , which may lead to lack of activation of Bdnf upregulation in the Mecp2 mutant brain. Indeed, we show here that BDNF protein level in the whole-brain lysate in Mecp2 mutant mice is decreased to about 70% of the wild-type level. We also observed similar phenotypes between the conditional Bdnf mutant mice and the Mecp2 mutant mice, suggesting that the moderate decrease in BDNF protein level may mediate some defects in the Mecp2 mutant mice. To further investigate the in vivo role of BDNF in RTT, we manipulated BDNF expression in the postnatal brains of Mecp2-deficient mice. We discovered that deleting Bdnf from the Mecp2 mutant brain resulted in an earlier onset/accelerated disease progression, whereas overexpressing BDNF in the Mecp2 mutant brain led to later onset/slower disease progression. Our findings provide in vivo evidence of a functional interaction between Mecp2 and Bdnf. Furthermore, our results indicate that manipulating the BDNF level or the BDNF signaling pathways may present therapeutic opportunities for RTT patients.
Results

Mecp2 Mutant Mice Express Decreased Levels of BDNF Protein
We used an ELISA assay to measure the level of BDNF protein in whole-brain protein extracts prepared from wild-type and Mecp2 mutants. At the presymptomatic stage (2 weeks of age), no difference was detectable between mutant and wild-type mice ( Figure 1A) . However, at an age when mice become symptomatic (6-8 weeks of age), we found that the BDNF protein level in Mecp2 mutant brains was 69% of the wild-type level (p = 0.01, Figure 1B ). To find out whether BDNF protein level is decreased throughout the brain or in specific subregions of the brain, we separated the brain into cortex, cerebellum, and the rest of the brain and again performed the ELISA assay. Because BDNF protein levels were decreased in mice displaying the typical mutant phenotype but not in mice at the presymptomatic stage, we examined brain subregions of symptomatic animals. At 7-8 weeks of age, we detected reduced levels of BDNF in all three subdivisions of the brain ( Figure 1C , 79% of the wild-type in the Mecp2KO cortex, p = 0.005; 59% of the wild-type in the Mecp2KO cerebellum, p = 0.009; and 45% of the wild-type in the rest of the Mecp2KO brain, p = 0.01, respectively).
Phenotypic Similarities between the Conditional
Bdnf Knockout Mice and the Mecp2 Mutant Mice To assess whether the decreased BDNF protein level may be involved in the neurological defects seen in Mecp2 mutant mice, we investigated whether Bdnf and Mecp2 mutant mice display phenotypic similarities. Because germline Bdnf knockout mice die shortly after birth (Ernfors et al., 1994) , we examined conditional Bdnf knockout mice that were generated previously by cre-mediated (cre93 transgene) deletion of a floxed Bdnf allele in postmitotic neurons throughout the forebrain, part of the midbrain, and hindbrain structures Rios et al., 2001) . Although Bdnf and Mecp2 mutants display significant phenotypic differences, we detected some anatomical and functional similarities between the respective mutants. As found in Mecp2 mutant mice, the average brain weight of Bdnf mutant mice was smaller than in wild-type animals ( Figure 1D) . A smaller brain weight is one of the pathological characteristics of RTT patients (Hagberg and Hagberg, 1997) . Furthermore, the size of CA2 neurons, as well as the size of olfactory glomeruli (a specialized synapse in the olfactory bulb), was reduced in both the Bdnf and the Mecp2 mutant mice as compared to their respective wild-type littermates ( Figures 1E and 1F and Figure S1 in the Supplemental Data available with this article online). Both the decrease of neuronal size ) and of the olfactory glomeruli size have been previously described in Mecp2 mutants (Matarazzo et al., 2004) . Finally, we observed a hindlimbclasping phenotype in Bdnf mutant mice ( Figure S2 ), which has been reported in Mecp2 mutants (Guy et al., 2001; Shahbazian et al., 2002) and is thought to mimic the stereotypic hand-wringing behavior in RTT patients. The phenotypic similarities between conditional Bdnf and Mecp2 mutants are consistent with the possibility that BDNF may mediate part of the late RTT pathologies (such as the small brain/neuron/synapse defects). Although our data suggest that BDNF and MeCP2 may regulate similar processes in the brain, they do not distinguish whether the two genes function through parallel or linear pathways. Based on these observations, we hypothesized that changes in BDNF expression level may modulate disease progression in Mecp2 mutant mice. We therefore tested whether deletion or overexpression of BDNF in the Mecp2 mutant brain would exacerbate or alleviate, respectively, the RTT-like symptoms. mice (DKO). When aged, the DKO mice showed a significantly shorter lifespan (light gray line, Figure 2A ) than the Mecp2 single-mutant mice (Mecp2KO) (black line, Figure 2A ). Survival of the Mecp2 mutants was affected by Bdnf dosage, because Mecp2 2/y ;cre93;Bdnf 2lox/+ mice (BdnfHet;Mecp2KO, medium gray line) had a shorter lifespan than the Mecp2KO mice but survived longer than the DKO mice ( Figure 2A ). Because both the cre93;Bdnf 2lox/2lox (BdnfKO, dashed line, Figure 2A ) and the cre93;Bdnf 2lox/+ (BdnfHet) mice have normal lifespans (Rios et al., 2001 ), the effect of BDNF level on the survival of Mecp2KO mice may reflect a functional interaction of the two genes.
Deletion of
Mecp2 mutant mice become lethargic and display decreased locomotor activity beginning at 6 weeks of age . To test whether Bdnf deletion in the brain of Mecp2 mutants may exacerbate locomotor dysfunction, we performed a dark-cycle locomotor activity assay (running-wheel assay). As shown in Figure 2B , the DKO mice showed a dramatically reduced level of running-wheel activity at 4 weeks of age, while neither the Mecp2 single mutants nor the Bdnf single mutants performed significantly differently from the wild-type mice at this age ( Figure 2B ). Thus, postnatal Bdnf deletion in the brain of Mecp2 mutants resulted in an earlier onset of locomotor dysfunction and earlier lethality than was seen in Mecp2 single mutants. 2/y ;cre93;Bdnf 2lox/2lox (DKO) mice. A log rank test (Harrington and Fleming, 1982) was performed to assess the statistical significance in the difference among the survival curves: BDNFhet; Mecp2KO versus Mecp2KO mice (p = 0.0096), DKO versus BDNFhet;Mecp2KO (p = 0.00031), and DKO versus Mecp2KO (p = 1.3E-07). Because the wild-type mice (WT) did not die during the time window studied here, their survival curve was not plotted in the graph. (B) A running-wheel assay was performed to assess the Bdnf deletion on the locomotor function of the Mecp2 mutant mice at 4 weeks of age. Total wheel-running activity of the wild-type was set as 100%. The activity value in other genotypes was normalized against the wild-type value to calculate the relative activity. N above each bar indicates the number of mice included for that genotype. All p values were from Student's t tests: Mecp2KO versus WT (p = 0.18), BdnfKO versus WT (p = 0.77), DKO versus WT (p = 0.0002). Data are presented as mean 6 SEM in all the bar graphs in this figure.
Generation of a Conditional BDNF-Overexpressing Allele
We next tested whether BDNF overexpression may delay the onset or alleviate the RTT-like symptoms in Mecp2 mutant mice. We engineered a conditional Bdnf overexpression transgene using the human BDNF cDNA (BDNF stop ) under regulation by the synthetic CAGGS promoter/enhancer/intron followed by a loxP-STOPloxP cassette. The transgene was targeted downstream of the collagen 1a1 locus by frt/Flpase-mediated sitespecific integration Hochedlinger et al., 2005) in V6.5 ES cells, which were injected into blastocysts to create the conditional BDNF stop mice. In the presence of cre recombinase, the STOP cassette is removed, resulting in activation of the BDNF transgene ( Figure 3A) . We crossed the BDNF stop mice with the cre93 mice to generate the BDNF stop ;cre93 mice (CAGGs-BDNF), and we examined Bdnf RNA and protein levels at different ages. When compared to control mice, Bdnf RNA levels were increased between 1.7-and 2.4-fold at 2, 5, and 10 weeks of age ( Figure 3C ). Similarly, ELISA detected correspondingly increased levels of BDNF protein ( Figure 3D ). To investigate the spatial pattern of BDNF transgene expression, we performed immunohistochemistry on brain sections using a BDNFspecific antibody. When compared with control sections, ectopic BDNF-transgene expression was readily detectable in the pyramidal neurons in the cortex and hippocampus of the CAGGs-BDNF mice ( Figure 3B ), as well as in other brain structures where the cre transgene was expressed (data not shown), reflecting the activity of the cre93 transgene ). Our results showed that cre93-mediated activation of the BDNF stop transgene resulted in an w2-fold increase of BDNF expression. No obvious pathological defects were observed in the CAGGs-BDNF mice (data not shown). Figure 2A) , overexpression of BDNF resulted in a significantly increased lifespan ( Figure 3E ). Consistent with improved viability of the CAGGsBDNF; Mecp2KO mice, we observed functional improvement in the running-wheel assay described above. At 6 weeks of age, when the Mecp2 mutant mice already show obvious symptoms, such as hindlimb clasping and reduced locomotor activity ( Figure 3F ), overexpression of BDNF resulted in a significant gain in locomotor function ( Figure 3F) .
Overexpressing BDNF in the Mecp2
One of the defects that are commonly observed in both human RTT patients and Mecp2 mutant mice is reduced brain size Hagberg, 1985; Hagberg and Hagberg, 1997) (Figure 1D ). Although the functional consequence of such a size reduction remains unclear, our results indicate that both BDNF and MeCP2 can affect the brain/neuron size. Therefore, we were interested to know whether BDNF overexpression in the Mecp2 mutant brain would partially rescue this defect. We observed a modest increase in brain weight in the CAGGsBDNF; Mecp2KO mice, compared to the Mecp2KO mice (Figure 3G , 0.35 g versus 0.329 g, p = 0.026).
Together, the common phenotypes seen in Bdnf and Mecp2 mutants ( Figures 1D-1F and Figures S1 and S2) , the accelerated development of symptoms in mice with combined Mecp2 and Bdnf deficiency (Figure 2) , and the partial rescue of symptoms in Mecp2 mutant mice that overexpress BDNF (Figure 3 ) demonstrate a functional interaction between these two genes.
Effects of BDNF Deletion and Overexpression on Cortical Physiology of the Mecp2 Mutant Mice
To define the mechanistic basis to the interaction between Bdnf and Mecp2, we tested whether Bdnf deletion or BDNF overexpression affected electrophysiological properties in Mecp2 mutant neurons. We performed whole-cell current-clamp recordings in layer 5 pyramidal neurons of the somatosensory cortex in mice of the respective genotypes based on our recent demonstration that acute slice preparations from Mecp2 mutant mice displayed a reduced spontaneous activity as compared to the wild-type littermate controls (Dani et al., 2005) . This defect was detectable in animals as young as 2 weeks of age and was most prominent in 5-week-old mutant mice. We investigated whether the deletion of Bdnf in Mecp2 mutant neurons would further reduce the spontaneous firing rate. At postnatal day 30, consistent with our previous result, we found that the firing rate of layer 5 pyramidal neurons of the somatosensory cortex from the Mecp2KO slices was reduced as compared to wt controls (0.85 Hz versus 3.72 Hz, p = 0.0038, Figure 4A ), while the firing rate in the BdnfKO slices was indistinguishable from the wt controls (4.62 Hz versus 3.72 Hz, p = 0.20). The averge firing rate of the DKO neurons was slightly lower than that of the Mecp2KO neurons (0.43 Hz versus 0.85 Hz, Figure 4A ), though this was not statistically significant (p = 0.44). In contrast, we found a significantly increased firing rate in pyramidal neurons from Mecp2 mutant mice that expressed ectopic BDNF when compared to the Mecp2 single mutants (2.84 Hz versus 0.94 Hz, p = 0.015, Figure 4B ). These results demonstrate that electrophysiological activity in Mecp2 mutant neurons correlates with BDNF levels, which in turn are associated with locomotor function and viability, further substantiating the functional interaction between Bdnf and Mecp2.
Discussion
In neurons, BDNF expression is tightly regulated by neuronal activity. At increased activity levels, the mechanism of activity-dependent Bdnf transcription involves calcium influx through voltage-gated calcium channel (Ghosh et al., 1994) , activation of Cam kinase IV (Shieh and Ghosh, 1999) , and phosphorylation of CREB (Tao et al., 1998) . Previously, we reported no difference in Bdnf RNA level (w100-fold of basal level) between Mecp2-deficient and wild-type neurons treated with KCl, which suggests that MeCP2 is not directly involved in the upregulation of Bdnf by increased activity (Chen et al., 2003) . Yet, when treated with tetrodotoxin (TTX), which blocks activity, a 2-fold increase of the Bdnf RNA level was detected in Mecp2-deficient as compared to wild-type neurons. This suggests that MeCP2 may function in the silencing of Bdnf basal transcription in activity-suppressed neurons (Chen et al., 2003) . Our present results found a lower level of BDNF protein in mutant brains, an observation which is in apparent conflict with the previous results (Chen et al., 2003) . To resolve this conflict, it is important to emphasize the differences in the previous and the present experimental design. Our previous experiments were performed in vitro and compared Bdnf RNA levels in homogeneous WT and Mecp2KO neuronal cultures where neuronal activity was artificially kept at an increased or suppressed level through KCl or TTX treatment, respectively. In contrast, the present study compared BDNF protein levels in wt (normal neuronal activity) and Mecp2KO (reduced neuronal activity) brains that are at different activity states. Given that BDNF expression depends on neuronal activity, we favor the hypothesis that Mecp2 deficiency reduces neuronal activity, thereby indirectly causing a decreased BDNF protein level. Consistent with this possibility, we found progressively reduced neuronal activity in layer 5 pyramidal neurons in the somatosensory cortex of Mecp2 mutant mice (Dani et al., 2005) . This chronic reduced activity in a major class of BDNFproducing neurons in the Mecp2 mutant brain is detectable at 2 weeks and may subsequently result in less activation of BDNF expression than the wild-type level. While our results demonstrate that the level of BDNF protein decreased in the Mecp2 mutants, the molecular mechanism is not clear. Previous results, based upon neural cultures, have demonstrated that the basal transcription rate of Bdnf promoter III is regulated by MeCP2. It will be interesting to investigate whether the other Bdnf promoters are also affected in the Mecp2 mutant brains.
BDNF is a well-known neurotrophic factor. The decreased level of BDNF protein in the Mecp2 mutant brain may contribute to the small brain/neuron/synapse defect, a typical atrophic response caused by Bdnf deficiency. The phenotypic similarities between the Mecp2 deficiency and the Bdnf deficiency are consistent with such a possibility. More importantly, the opposing effects of Bdnf deletion and overexpression on the survival, locomotor function, and cortical physiology of the Mecp2 mutant mice are consistent with a functional interaction between BDNF and MeCP2 in RTT pathogenesis. Although our data do not distinguish whether MeCP2 and BDNF signal through parallel or linear pathways, they suggest that BDNF and MeCP2 may regulate the same biological process. It will be important to define what downstream targets of BDNF overlap with the affected targets in the Mecp2 mutant mice.
Several aspects of the Mecp2 mutant phenotype were ameliorated by postnatal ectopic expression of BDNF. For example, BDNF overexpression markedly improved the locomotor function of the Mecp2 mutant mice in the dark-cycle running-wheel assay. It is possible that the improved motor function allows mutant mice more efficient access to food and water, which may, at least in part, explain the significant extension of lifespan. Furthermore, BDNF overexpression rescued an electrophysiological deficit in the Mecp2 mutant cortex, resulting in an increased spontaneous firing of layer 5 pyramidal neurons. This result is consistent with many previous reports that studied the effect of BDNF on synaptic transmission (Schuman, 1999) . It is possible that the overexpression of BDNF in Mecp2 mutant brains also increased neuronal activity in other parts of the brain, such as the motor cortex, which contributed to the enhanced locomotor function.
Abnormal BDNF expression has been linked to many human diseases, such as Huntington's disease (Canals et al., 2004) , schizophrenia, and depression (Angelucci et al., 2005) . Our finding links Bdnf and Mecp2 in vivo and suggests that RTT may be another human disease that is partially mediated through BDNF. Moreover, overexpression of such a pleotrophic factor in the brain has been shown to ameliorate symptoms in a mouse model of Huntington's disease (Cepeda et al., 2004; Kells et al., 2004) . Similarly, our results suggest therapeutic opportunities through manipulation of BDNF expression. Although Bdnf is only one of many genes regulated by MeCP2, it is the first one shown to modulate disease progression of Mecp2 mutant mice. Future studies will be aimed at understanding the molecular basis that underlies its effect on the course of RTT disease.
Experimental Procedures
Mice Mating and Genotyping Many of the mouse alleles used in this study have been reported previously. These include the conditional Bdnf knockout allele (Rios et al., 2001) , the cre93 transgene , and the Mecp2 germline mutant allele . Genotyping of these alleles was performed as described in these papers. A PCR assay was developed to genotype the conditional BDNF overexpression allele. 
Generation of Conditional BDNF-Overexpressing Mice
An MluI/NotI fragment containing human BDNF cDNA with an HA tag was cut out from pAdCIG (a gift from Dr. Rita Balice-Gordon), bluntended, and ligated with an EcoRI cut/blunt-ended pCAGGSTurbocre vector to generate pCAGGS-BDNF-HA. A SpeI/SfiI fragment containing the CAGGS promoter, the BDNF cDNA, the HA tag, and an RBGpolyA signal was cut out from the pCAGGS-BDNF-HA and subcloned into the EcoRV site of pPGK-ATG-FRT (no EcoRI) vector. A loxP-STOP-loxP cassette was cloned immediately upstream of the BDNF cDNA to generate the conditional BDNF-overexpressing construct. The procedure to flip-in the conditional BDNF-overexpressing construct into the modified collagen 1a1 locus in ES cells was done as previously described . Hygromycinresistant ES clones were analyzed by Southern blot. Correctly targeted ES clones were expanded and frozen. For diploid blastocyst injections, fertilized zygotes were isolated from the oviducts of day 0.5 pregnant B6D2F1 females and allowed to develop to the blastocyst stage in culture. About ten ES cells were injected per blastocyst. Injected blastocysts were transferred into day 2.5 pseudopregnant or Swiss recipient females. Chimeric mice were bred with C57B6 mice to screen for germline transmission by coat color.
BDNF ELISA
A BDNF ELISA kit (Promega) was used to measure BDNF protein expression as per the manufacturer's instructions. All solutions were from the kit or made exactly as instructed by the manufacturer.
Neuron
Brains from specified ages were freshly isolated (subdivided into subregions of the brain in certain experiments) and lysed. Total protein concentration was measured by using a Dc Protein Assay kit from BIO-RAD. An acid treatment of the brain lysate was adopted to increase the amount of free BDNF. In each assay, duplicate wells were assigned for each sample. A VERSAmax microplate reader was used to measure signal intensity from the wells. A standard curve was generated from the BDNF standard wells on each plate, using the SPF3.1.2 software. The total amount of BDNF per well was calculated based on the standard curve. The relative BDNF value was then calculated by normalizing the amount of BDNF against the total protein input.
Brain Weight, Immunohistochemistry, and CA2 Neuron Measurement For brain weight analysis, brains were freshly isolated and weighed. For CA2 neuron measurement, brains were perfused with 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4), postfixed in 4% paraformaldehyde overnight at 4ºC, washed in PBS, processed by a TISSUE-TEK VIP machine (Miles Scientific), and imbedded in paraffin. Five-micron serial coronal sections were taken through the whole brain. Digital pictures were taken for the CA2 region of the hippocampus. The soma area (arbitrary unit) of projection neuron was determined by tracing the outline of the neuronal cell body cut through the level of the nucleolus, using OpenLab software. For immunohistochemistry, brains were perfused with 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4), postfixed in 4% paraformaldehyde overnight at 4ºC, cryoprotected in 20% sucrose, imbedded in OCT, and frozen on dry ice. Fifty-micron serial coronal sections were taken through the whole brain. Floating sections were stained with a rabbit polyclonal BDNF-specific antibody (Chemicon), followed by a biotinylated goat anti-rabbit secondary antibody, and visualized with an immuno-peroxidase stain (Vector).
Quantitative PCR Total RNA was isolated by using the Absolutely RNA TM RT-PCR Miniprep kit (Stratagene). One microgram of RNA from each sample was used to generate cDNA, by using the SuperScript TM First-Strand Synthesis System for RT-PCR kit (Invitrogen). Two microliter of the total RT product was used for each PCR reaction. CyberGreen dye (Molecular Probes) and HotStar Taq (Qiagen) were included in the PCR mix. Two sets of primers for Bdnf and one set of primers for GAPDH were used. Bdnf set 1: 5 0 -AGAGCTGTTGGATGAGGACC AG-3 0 (forward), 5 0 -CAAAGGCACTTGACTACTGAGCA-3 0 (reverse). Bdnf set 2: 5 0 -TACGAGACCAAGTGCAATCCC-3 0 (forward), 5 0 -CGCA CGTACGACTGGGTAGTT-3 0 (reverse). GAPDH set: 5 0 -AATGGGAAG CTTGTCATCAACG-3 0 (forward), 5 0 -GAAGACACCAGTAGACTCCAC GACATA-3 0 (reverse). Triplicate reactions were run for each sample for both BDNF and GAPDH. Reactions were run on the ABI PRISM 7000 Sequence Detection System (Applied Biosystems). Threshold cycle for each reaction was determined, using the ABI Prism 7000 SDS software (Applied Biosystems). Bdnf values were first normalized against the GAPDH values for each sample. Normalized wildtype values were set as 100% to calculate relative values.
Dark-Cycle Running-Wheel Activity Assay
Total dark-cycle running-wheel activities were recorded in a wheel running cage connected to a Mini-counter (Opto-Varimax-Mini-A, Columbus Instruments). For each measurement, a mouse was placed at least 3 hr before the starting time into a standard laboratory mouse cage with fresh bedding. Recording started at the time when the lights were normally turned off (19:00 Eastern Standard Time) and stopped at 8:00 the next morning, 1 hr after the lights normally came back on. Wild-type activity was set as 100% to calculate relative activity in the other genotypes.
Electrophysiology
The standard artificial cerebrospinal fluid (ACSF) contained (in mM) NaCl, 126; KCl, 3; MgSO 4 , 2; NaHPO 4 , 1; NaHCO 3 , 25; CaCl 2 , 7; H 2 O, 2; and Dextrose, 14. For spontaneous firing, the ACSF was modified as follows: KCl, 3.5; MgCl 2 , 0.5; CaCl 2 , 1. Osmolality was adjusted to 318 6 2 mOsm. Whole-cell pipette solution contained (in mM) KCl, 20; K-Gluconate, 100; HEPES, 10; Biocytin 0.1% (w/v); Mg-ATP, 4; Na-GTP, 0.3, and Na-Phosphocreatinine, 10. Threehundred mm thick coronal sections containing the somatosensory cortex were cut in cold ACSF using a Leica VT1000S slicer. Slices were incubated in standard ACSF at 37ºC for 15-20 min immediately after slicing and subsequently at room temperature. Slices were preincubated (w45 min) and perfused in modified ACSF as previously described (Maffei et al., 2004) . Somatic whole-cell recordings were obtained from visually identified layer 5 (L5) pyramidal cells as previously described (Dani et al., 2005) . Glass pipette electrodes (4-6 MU resistance) were pulled from borosilicate capillaries (World Precision Instruments, Inc, Sarasota, FL) using a Sutter P92 Flame/Brown Puller (Sutter Instruments Co, Novato, CA). All data acquisition and analysis were performed using Igor Pro (Wavemetrics, Lake Oswego, OR) software and in-house programs. Data were acquired using a Multiclamp 700A (Axon Instruments/Molecular Devices, Union City, CA) computer-controlled amplifier at 10 KHz and low-pass filtered at 3 KHz. In all experiments, slices were fixed and stained for biocytin to confirm the identity of the recorded cells.
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